Online inquiry

IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5826MR)

This product GTTS-WQ5826MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E gene. The antibody can be applied in Psoriasis, Type 1 diabetes research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916
UniProt ID P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5826MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14583MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ12694MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ905MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-221
GTTS-WQ5703MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ8027MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ13645MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ6701MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ7587MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA G-CSF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW